Early and Longitudinal Humoral Response to the SARS-CoV-2 mRNA BNT162b2 Vaccine in Healthcare Workers: Significance of BMI, Adipose Tissue and Muscle Mass on Long-Lasting Post-Vaccinal Immunity

Viruses. 2022 Apr 22;14(5):868. doi: 10.3390/v14050868.

Abstract

Background: This study aimed to investigate the early and longitudinal humoral response in Healthcare Workers (HCWs) after two doses of the BNT162b2 vaccine and to assess the association between metabolic and anthropometric parameters and the humoral response after vaccination.

Methods: The study included 243 fully vaccinated HCWs: 25.50% previously infected with SARS-CoV-2 (with prior history of COVID-19-PH) and 74.40%-uninfected, seronegative before the first vaccination (with no prior history of COVID-19-NPH). IgG antibodies were measured, and sera were collected: prior to the vaccination, 21 days after the first dose, and 14 days and 8 months after the second dose.

Results: 21 days after the first dose, 90.95% of individuals were seropositive; 14 days after the second dose, persistent immunity was observed in 99.18% HCWs, 8 months after complete vaccination-in 61.73%. Statistical analysis revealed that HCWs with PH had a greater chance of maintaining a humoral response beyond eight months after vaccination. Increased muscle mass, decreased fat mass, and younger age may positively affect long-term immunity. Smokers have a reduced chance of developing immunity compared to non-smokers.

Conclusions: Fully vaccinated HCWs with PH are more likely to be seropositive than fully inoculated volunteers with NPH.

Keywords: BNT162 vaccine; COVID-19; COVID-19 vaccine; IgG antibody; SARS-CoV-2; adipose tissue; body composition; health care professionals; healthcare workers; immunization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue
  • BNT162 Vaccine
  • Body Mass Index
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Health Personnel
  • Humans
  • Muscles
  • Muscular Diseases*
  • RNA, Messenger
  • SARS-CoV-2
  • Vaccines*

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • Vaccines
  • BNT162 Vaccine